Urinary adiponectin excretion: A novel marker for vascular damage in type 2 diabetes

Diabetes

Volumn 58, Issue 9, 2009, Pages 2093-2099

  Von Eynatten, Maximilian ^a,b   Liu, Dan ^a   Hock, Cornelia ^c   Oikonomou, Dimitrios ^b   Baumann, Marcus ^a   Allolio, Bruno ^c   Korosoglou, Grigorios ^b   Morcos, Michael ^b   Campean, Valentina ^d   Amann, Kerstin ^d   Lutz, Jens ^a   Heemann, Uwe ^a   Nawroth, Peter P ^b   Bierhaus, Angelika ^b   Humpert, Per M ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALBUMIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CAROTID ARTERY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; URINARY EXCRETION; WESTERN BLOTTING;

ADIPONECTIN; AGED; BIOLOGICAL MARKERS; BIOPSY; BLOTTING, WESTERN; CAROTID ARTERY DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 70349101696     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-0204     Document Type: Article

References (30)

1. Bianchi C, Miccoli R, Penno G, Del Prato S. Primary prevention of cardiovascular disease in people with dysglycemia. Diabetes Care 2008;31(Suppl. 2):S208-S214
2. Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS, the Atherosclerosis Risk in Communities Study Investigators. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care 2003;26:2777-2784
3. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696
4. Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
6. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlöv J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-2116 (Pubitemid 351679597)
7. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, Boerwinkle E, Mosley TH Jr, Sorlie P, Diao G, Sharrett AR. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 2006;166:1368-1373 (Pubitemid 44036348)
8. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-1737 (Pubitemid 38489895)
9. von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D. Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J 2008;29:1307-1315 (Pubitemid 351768129)
10. Maiolino G, Cesari M, Sticchi D, Zanchetta M, Pedon L, Antezza K, Pessina AC, Rossi GP. Plasma adiponectin for prediction of cardiovascular events and mortality in high-risk patients. J Clin Endocrinol Metab 2008;93:3333-3340
11. Looker HC, Krakoff J, Funahashi T, Matsuzawa Y, Tanaka S, Nelson RG, Knowler WC, Lindsay RS, Hanson RL. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004;89:4010-4017 (Pubitemid 39071508)
12. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451
13. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, Ouedraogo R, Hough K, McCue P, Chan L, Falkner B, Goldstein BJ. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008;118:1645-1656 (Pubitemid 351632369)
14. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-1197 (Pubitemid 27274286)
15. Han WK, Alinani A, Wu CL, Michaelson D, Loda M, McGovern FJ, Thadhani R, Bonventre JV. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol 2005;16:1126-1134 (Pubitemid 41710324)
16. Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006;103:10391-10396
17. von Eynatten M, Liu D, Bluemm A, Schuster T, Baumann M, Lutz J, Heemann U, Dugi K, Nawroth P, Bierhaus A, Humpert P. Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes. Clin Endocrinol doi10.1111/j.1365-2265.2008.03412.x, 2008
18. Humpert PM, Papadopoulos G, Schaefer K, Djuric Z, Konrade I, Morcos M, Nawroth PP, Bierhaus A. sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. Horm Metab Res 2007;39:899-902
19. Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type 2 diabetes (UKPDS 56). Clin Sci 2001;101:671-679
20. Redberg RF, Greenland P, Fuster V, Pyörälä K, Blair SN, Folsom AR, Newman AB, O'Leary DH, Orchard TJ, Psaty B, Schwartz JS, Starke R, Wilson PW. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group III: risk assessment in persons with diabetes. Circulation 2002;105:e144-e152
21. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 2007;30:1292-1293 (Pubitemid 46684668)
22. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-360
23. Sukhija R, Aronow WS, Kakar P, Garza L, Sachdeva R, Sinha A, Mehta JL. Relation of microalbuminuria and coronary artery disease in patients with and without diabetes mellitus. Am J Cardiol 2006;98:279-281 (Pubitemid 44062430)
24. Sarafidis PA, Bakris GL. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant 2006;21:2366-2374 (Pubitemid 44644505)
25. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S, HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-426 (Pubitemid 32681484)
26. Hunt KJ, Williams K, Rivera D, O'Leary DH, Haffner SM, Stern MP, González Villalpando C. Elevated carotid artery intima-media thickness levels in individuals who subsequently develop type 2 diabetes. Arterioscler Thromb Vasc Biol 2003;23:1845-1850 (Pubitemid 37254873)
27. Gerstein HC, Mann JF, Pogue J, Dinneen SF, Hallé JP, Hoogwerf B, Joyce C, Rashkow A, Young J, Zinman B, Yusuf S. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care 2000;23(Suppl. 2):B35-B39
28. Mäkinen VP, Forsblom C, Thorn LM, Wadén J, Gordin D, Heikkilä O, Hietala K, Kyllönen L, Kytö J, Rosengård- Bärlund M, Saraheimo M, Tolonen N, Parkkonen M, Kaski K, Ala-Korpela M, Groop PH, the Finn-Diane Study Group. Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes 2008;57:2480-2487
29. Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M, Igura T, Inui Y, Kihara S, Nakamura T, Yamashita S, Miyagawa J, Funahashi T, Matsuzawa Y. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000;32:47-50 (Pubitemid 30143606)
30. Ohashi K, Iwatani H, Kihara S, Nakagawa Y, Komura N, Fujita K, Maeda N, Nishida M, Katsube F, Shimomura I, Ito T, Funahashi T. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 2007;27:1910-1917 (Pubitemid 47312299)